Drug Profile
Research programme: anti-infectives - Welichem Biotech
Alternative Names: Anti-infectives research programme - Welichem Biotech; Infectious diseases research programme - Welichem BiotechLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Welichem Biotech
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in Canada
- 05 Mar 2003 Preclinical trials in Bacterial infections in Canada (unspecified route)